Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
Loading...
Embargo End Date
ICR Authors
Authors
van Wamel, A
Sontum, PC
Healey, A
Kvåle, S
Bush, N
Bamber, J
de Lange Davies, C
Sontum, PC
Healey, A
Kvåle, S
Bush, N
Bamber, J
de Lange Davies, C
Document Type
Journal Article
Date
2016-08-28
Date Accepted
2016-06-09
Abstract
Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong increase in therapeutic efficacy; 120days after study start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group and the median survival was increased by 86%. In combination with Abraxane® (12mg paclitaxel/kg given i.v.), ACT induced a strong increase in the therapeutic efficacy; 60days after study start 100% of the animals were in stable, remission vs. 0% for the Abraxane® only group, 120days after study start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane® only group. For the ACT+Abraxane group 100% of the animals were alive after 120days vs. 0% for the Abraxane® only group. Proof of concept for Acoustic Cluster Therapy has been demonstrated; ACT markedly increases the therapeutic efficacy of both paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
Citation
Journal of controlled release : official journal of the Controlled Release Society, 2016, 236 pp. 15 - 21
Source Title
Publisher
ELSEVIER SCIENCE BV
ISSN
0168-3659
eISSN
1873-4995
Collections
Research Team
Ultrasound & Optical Imaging